Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Latigo Biotherapeutics, Inc. (LTGO)

22.48 +0.71 (+3.26%)
At close: 4:00:01 PM EDT
22.92 +0.44 (+1.96%)
After hours: 4:24:31 PM EDT
Chart Range Bar
Loading chart for LTGO
  • Previous Close 21.77
  • Open 21.99
  • Bid 22.50 x 100
  • Ask 21.94 x 100
  • Day's Range 21.83 - 23.41
  • 52 Week Range 17.22 - 25.93
  • Volume 229,298
  • Avg. Volume 388,357
  • Market Cap (intraday) 1.422B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.85
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 52.25

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.

latigobio.com

59

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LTGO
7.05%
S&P 500 (^GSPC)
13.18%

1-Year Return

LTGO
7.05%
S&P 500 (^GSPC)
20.15%

3-Year Return

LTGO
7.05%
S&P 500 (^GSPC)
71.57%

5-Year Return

LTGO
7.05%
S&P 500 (^GSPC)
70.83%

Analyst Insights

View More

Analyst Price Targets

36.00
52.25 Average
22.48 Current
73.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/1/2026
Analyst Leerink Partners
Rating Action Initiated
Rating Outperform
Price Action Announces
Price Target 36

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    1.41B

  • Enterprise Value

    1.37B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -111.18M

  • Diluted EPS (ttm)

    -1.85

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    42.18M

  • Total Debt/Equity (mrq)

    1.54%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: